Suzhou Lixin Pharmaceutical Co., Ltd

Since its establishment in 2000, Lixin Pharmaceutical Co., Ltd. has adhered to the goal of serving the global regulatory pharmaceutical market. Through technological innovation and standardized management, the company is continually developing and producing high-quality APIs and intermediates to meet the human pursuit of high-quality drugs. Adhering to corporate culture of scientific, rigorous, and standardized, advocating the spirit of innovation, and focus on the development and application of safety, environmental-friendly, low consumption, and high-quality original process technologies, Lixin Pharmaceutical has gradually established the production lines in the fields of anti-tumor, cardiovascular, antiviral, and digestive systems. Lixin has over 30 international invention patents in China, the United States, Europe, and other regions, forming a company-own intellectual property system. Lixin has submitted 4 DMF of API to US FDA, and obtained 8 CEP, NMPA new drug certificates, and over 20 domestic GMP certificates. Meanwhile, more than 20 products are under development for both domestic and foreign market, which laying a solid foundation for the company's sustainable development. Lixin Pharmaceutical adheres to the implementation of a globally standardized GMP management system and continuously improves and pursues excellence. The company has a R&D center with a total area of over 3000 square meters. There are two GMP factories located in Suzhou city of Jiangsu province and Zibo city of Shandong province. Both factories have multiple GMP workshops and professional APIs production lines, equipped with advanced sewage treatment systems and other supporting facilities. The factories have passed multiple inspections by NMPA, US FDA, EDQM, and EMA, and will provide high-quality services to global pharmaceutical companies through a sustainable and healthy development philosophy.